Ermanno Greco

Ermanno Greco

Auto-generated profile, based on publicly available information

Ermanno Greco

Department of Reproductive Medicine, Rome, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Fertility and Sterility
Verified
Journal Article
Closed access
FSFrancesca Spinella
Francesca Spinella
FFFrancesco Fiorentino
Francesco Fiorentino
ABAnil Biricik
Anil Biricik
SBSara Bono
Sara Bono
ARAlessandra Ruberti
Alessandra Ruberti
EGErmanno Greco
Ermanno Greco

1 December 2019 in Fertility and Sterility
Verified
Journal Article
Closed access
LRLaura Rienzi
Laura Rienzi
Danilo CimadomoDanilo Cimadomo
Danilo Cimadomo
ADArantxa Delgado
Arantxa Delgado
MMMaria Giulia Minasi
Maria Giulia Minasi
GFGemma Fabozzi
Gemma Fabozzi
MMMarcos Meseguer
Marcos Meseguer

25 August 2022 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
AMAntonio La Marca
Antonio La Marca
MCMartina Capuzzo
Martina Capuzzo
MLMaria Longo
Maria Longo
MIMaria Giovanna Imbrogno
Maria Giovanna Imbrogno
GSGiorgio Alfredo Spedicato
Giorgio Alfredo Spedicato
EGErmanno Greco
Ermanno Greco
Can the possibility of having at least one euploid blastocyst for embryo transfer and the total number of euploid blastocysts be predicted for couples before they enter the IVF programme? Ovarian reserve and female age are the most important predictors of having at least one euploid blastocyst and the total number of euploid blastocysts. The blastocyst euploidy rate among women undergoing ART has already been shown to significantly decrease with increasing female age, and the total number of euploid embryos is dependent on the blastocyst cohort size. However, the vast majority of published studies are based on retrospective analysis of data. This prospective analysis included 847 consecutively enrolled couples approaching their first preimplantation genetic testing for aneuploidies (PGT-A) cycle between 2017 and 2020. Only couples for whom ejaculated sperm was available and women with a BMI of <35 kg/m2 were included in the study. Only the first cycle was included for each patient. The study was conducted at an IVF centre where, for all patients, the planned treatment was to obtain embryos at the blastocyst stage for the PGT-A programme. The impact of the following covariates was investigated: a woman’s serum AMH level, age, height, weight and BMI and a man’s age, height, weight, BMI, sperm volume and sperm motility and morphology. The analysis was performed with a machine learning (ML) approach. Models were fit on the training set (677 patients) and their predictive performance was then evaluated on the test set (170 patients). After ovarian stimulation and oocyte insemination, 40.1% of couples had at least one blastocyst available for the PGT-A. Of 1068 blastocysts analysed, 33.6% were euploid. Two distinct ML models were fit: one for the probability of having at least one euploid blastocyst and one for the number of euploid blastocysts obtained. In the training set of patients, the variable importance plots of both models indicated that AMH and the woman’s age are by far the most important predictors. Specifically, a positive association between the outcome and AMH and a negative association between the outcome and female age appeared. Gradient-boosted modelling offers a greater predictive performance than generalized additive models (GAMs). The study was performed based on data from a single centre. While this provides a robust set of data with a constant ART process and laboratory practice, the model might be suitable only for the evaluated population, which may limit the generalization of the model to other populations. ML models indicate that for couples entering the IVF/PGT-A programme, ovarian reserve, which is known to vary with age, is the most important predictor of having at least one euploid embryo. According to the GAM, the probability of a 30-year-old woman having at least one euploid embryo is 28% or 47% if her AMH level is 1 or 3 ng/ml, respectively; if the woman is 40 years old, this probability is 18% with an AMH of 1 ng/ml and 30% with an AMH of 3 ng/ml. This study was supported by an unrestricted grant from Gedeon Richter. The authors declared no conflict of interests. N/A.

4 January 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
EGErmanno Greco
Ermanno Greco
PYPavel Yakovlev
Pavel Yakovlev
NKNikolay Kornilov
Nikolay Kornilov
SVSvetlana Vyatkina
Svetlana Vyatkina
DBDaria Bogdanova
Daria Bogdanova
MVManuel Viotti
Manuel Viotti
The health risks associated with transferring embryos classified as mosaic by preimplantation genetic testing for aneuploidies (PGT-A) are currently unknown. Such embryos produce PGT-A results indicating the presence of both euploid and aneuploid cells and have historically been deselected from transfer and grouped with uniformly aneuploid embryos as ‘abnormal’. In recent years, numerous groups have reported the intentional transfer of mosaic embryos in the absence of uniformly euploid embryos, largely observing births of seemingly healthy babies. However, it remains to be understood whether the embryonic mosaicism invariably becomes resolved during the ensuing pregnancy, or whether the placenta and/or fetal tissues retain aneuploid cells, and if so to what potential clinical effect. Here, we report two cases of mosaicism persisting from the embryonic stage to the established pregnancy. Case 1 involved an embryonic low-level segmental mosaic loss in Chromosome (Chr) 1, which was confirmed in amniocentesis as well as in brain tissue of the products of conception. This pregnancy was terminated due to the chromosomal pathologies associated with 1p36 deletion syndrome, such as severe intellectual disability. Case 2 involved a low-level mosaic Chr 21 trisomy, which was confirmed with chorionic villus sampling and amniocentesis. The ensuing pregnancy was terminated after ultrasound identification of severe abnormalities in the placenta and fetus. Together, these two cases should be taken into account for risk-benefit assessments of prospective mosaic embryo transfers.

7 October 2021 in Fertility and Sterility
Verified
Journal Article
Closed access
MVManuel Viotti
Manuel Viotti
RMRajiv C. McCoy
Rajiv C. McCoy
Darren GriffinDarren Griffin
Darren Griffin
FSFrancesca Spinella
Francesca Spinella
EGErmanno Greco
Ermanno Greco
CZChristo G. Zouves
Christo G. Zouves

20 July 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
AMA La Marca
A La Marca
VDV Donno
V Donno
MLM Longo
M Longo
PGP Greco
P Greco
FCF Cucinelli
F Cucinelli
EGE Greco
E Greco
Can anti-Müllerian hormone (AMH) help predict how many oocytes will be retrieved following double stimulation (DuoStim)? A simple clinical tool can use serum AMH values to predict ovarian response following DuoStim in IVF cycles. The knowledge that multiple follicular waves arise during a single ovarian cycle has led to the introduction of unconventional ovarian stimulation protocols. The DuoStim protocol involves two successive ovarian stimulations performed during a single ovarian cycle and has been proposed as an approach for patients with poor ovarian response and for medical fertility preservation. As AMH has been used as a marker of ovarian reserve and stimulation response, the current study aimed to investigate the diagnostic performance of AMH in predicting the number of retrieved oocytes following DuoStim. This is a retrospective observational study involving 116 patients who received IVF treatment from January 2021 to September 2022. The study was conducted at a private IVF centre. Only patients who had their AMH measured prior to treatment and had complete patient records regarding their clinical and IVF/ICSI cycle characteristics were included. The primary outcome was the correlation between AMH values and the number of oocytes retrieved following DuoStim. Parametric and non-parametric tests were used to compare baseline characteristics and outcomes. Spearman’s R was used to analyse correlations between variables, while the C statistic was used to calculate the diagnostic performance of AMH. AMH levels were significantly correlated with the total number of oocytes retrieved after the DuoStim (R 0.61; CI 0.44–0.70; P < 0.0001). The difference in the total number of oocytes retrieved between the first (median 4 oocytes, interquartile range (IQR) 2–6) and second (median 6 oocytes, IQR 3.2–8) stimulation was statistically significant (P < 0.0001). However, there was no significant difference in the number of mature oocytes that were retrieved (median of 3 and 4 in the first and second stimulations, respectively). After the first stimulation, 68% of patients had at least one blastocyst available, while after the second stimulation, 74% did (NS). Based on linear regression, each 0.25 ng/ml increase in basal AMH corresponds to one additional oocyte recovered at the end of both stimulations (R2: 0.32, P < 0.0001). The results are limited owing to the observational nature of the study and the number of participants. Counselling infertile couples regarding the intermediate outcome of IVF (i.e. number of retrieved oocytes) is one of the most demanding tasks that clinicians face. To our knowledge, this is the first study that provides an easy-to-use clinical tool that enables the quantitative prediction of ovarian response following DuoStim, based on serum AMH values. No external funding was obtained for this study. The authors declare no conflicts of interest. N/A.